Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Oral)
Medically reviewed by Drugs.com. Last updated on Jun 11, 2022.
Warning: Post-treatment Acute Exacerbation of Hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted .
Commonly used brand name(s)
In the U.S.
- Genvoya
Available Dosage Forms:
- Tablet
Therapeutic Class: Anti-Infective Agent
Pharmacologic Class: Integrase Inhibitor
Uses for elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is usually given to patients who have yet not received any medicine for HIV infection.
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide will not keep you from spreading HIV to other people. People who receive elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide may continue to have other problems usually related to AIDS or HIV disease.
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is available only with your doctor's prescription.
Before using elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide combination in children weighing less than 25 kilograms. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefuln..
